Zanidatamab before surgery for HER2 positive colon or rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon or rectal cancer that can be removed with surgery and your doctor plans to treat it with a goal of cure.
- Your cancer has a high level of a protein called HER2 (tested on a biopsy sample).
- Your cancer does not have changes in a gene called RAS (wildtype means no mutation).
- You are at least 18 years old.
- You are in generally good health, able to care for yourself (ECOG score 0-2).
- You have adequate kidney, liver, and heart function as shown by blood tests and an echocardiogram (heart ultrasound).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
This trial tests whether a targeted drug (zanidatamab, which attacks HER2-positive cancer cells) combined with chemotherapy can shrink stomach cancer before surgery, making it easier to remove. It may also help people whose cancer has spread a bit, by making it operable.
This trial tests a drug called zanidatamab for people with advanced solid tumors that have a specific marker called HER2. It may help if you've already tried one or more standard treatments.
This trial tests a new drug called zanidatamab given together with standard chemotherapy before surgery for a type of stomach or junction cancer that is HER2-positive (has a specific protein). The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests a combination of two medications (zanidatamab and tislelizumab) for people with HER2-positive gastrointestinal cancers. It aims to see if this treatment can shrink tumors or prevent recurrence in early-stage cancers, and provide a new option for advanced colorectal cancer.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Hear when a new Colon Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.